---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-002072"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:02:03.259169+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kiniksa reports preliminary ARCALYST revenue of $122.5M for FY2022; cash $190.4M

## Summary
- ARCALYST net revenue Q4 2022 $39.9M, full-year $122.5M (unaudited).
- Year-end 2022 cash, equivalents and ST investments $190.4M, funding into at least 2025.
- Greater than 800 prescribers for recurrent pericarditis; 22% have prescribed for 2+ patients.
- Payer approval rate >90%; approx 45% of patients who discontinued ARCALYST restarted therapy.
- KPL-404 Phase 2 RA trial: 2 of 3 cohorts enrolled; proof-of-concept data expected 1H 2024.

## SEC filing metadata
- accession: 0001104659-23-002072
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465923002072/0001104659-23-002072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465923002072/tm232503d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-002072
- JSON: https://secwatch.observer/filing/0001104659-23-002072.json
- Plain text: https://secwatch.observer/filing/0001104659-23-002072.txt

## Key facts
- Earnings Releases
  Kiniksa Pharmaceuticals International, plc reported the fourth quarter of 2022 results: revenue $39.9 million.
  - Period: the fourth quarter of 2022
  - Revenue: $39.9 million
  - Result: preliminary results
  source text: ARCALYST net revenue was $39.9 million and $122.5 million for the fourth quarter and full year 2022, respectively (unaudited).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730430/000110465923002072/0001104659-23-002072-index.htm
- Earnings Releases
  Kiniksa Pharmaceuticals International, plc reported the full year 2022 results: revenue $122.5 million.
  - Period: the full year 2022
  - Revenue: $122.5 million
  - Result: preliminary results
  source text: ARCALYST net revenue was $39.9 million and $122.5 million for the fourth quarter and full year 2022, respectively (unaudited).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730430/000110465923002072/0001104659-23-002072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.